10/30/2024
5:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form SC 13G | |
10/22/2024
3:18 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:19 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:21 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:22 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:23 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
10/22/2024
3:17 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/18/2024
5:42 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:27 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:42 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:10 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:17 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:57 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:00 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
4:06 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/15/2024
3:38 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/10/2024
7:36 PM | Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
7:38 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
7:39 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/09/2024
3:27 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/09/2024
3:16 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/08/2024
5:54 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:56 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:57 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:58 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:28 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
5:43 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:44 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:45 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:47 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/01/2024
6:53 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/30/2024
3:19 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/18/2024
3:17 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/03/2024
4:43 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/29/2024
5:36 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
6:48 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/19/2024
6:49 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/19/2024
3:32 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/19/2024
3:32 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
3:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad) Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention. Get your FREE, no-obligation Wealth Protection Guide now |
08/02/2024
6:23 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:25 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:26 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:22 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
6:31 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
6:33 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
3:30 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/31/2024
3:31 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/29/2024
5:12 PM | 5AM Ventures VI, L.P. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form SC 13D/A | |
07/29/2024
4:39 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/29/2024
3:15 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/25/2024
3:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/17/2024
6:25 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
4:37 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
4:34 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/15/2024
3:12 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
3:48 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
3:48 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024
3:31 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2024
7:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
3:35 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
3:38 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/25/2024
2:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2024
6:20 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:12 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
3:24 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/10/2024
5:46 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
4:54 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
4:56 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/29/2024
3:06 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K/A | |
05/29/2024
3:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/28/2024
4:45 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/28/2024
4:29 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2024
6:46 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/20/2024
4:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Gupta Rishi (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
2:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/17/2024
2:11 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/17/2024
2:04 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
6:29 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
4:23 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
4:23 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/14/2024
3:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/14/2024
3:10 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
6:35 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2024
7:40 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/07/2024
5:58 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2024
6:02 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2024
6:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/30/2024
11:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form EFFECT | |
04/30/2024
3:16 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 424B3 | |
We recommended Nvidia in 2016, now we’re recommending this… (Ad) The Pentagon has just made a critical $7.7 billion move.
They're investing into one of the most controversial technologies the world has ever known…
A technology I’m calling “The AI Keystone”, because without it, the AI industry is doomed. Click here to watch his special investigative report into the controversial ‘AI Keystone’. |
04/29/2024
5:50 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2024
3:11 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
3:16 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form ARS | |
04/18/2024
3:44 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/15/2024
6:02 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:05 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:06 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
